EAST WINDSOR, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application diclofenac sodium topical solution USP, 2% w/w. Aurobindo Pharma’s diclofenac sodium topical solution, are an AB-rated generic equivalent to the reference listed drug (RLD), Pennsaid Topical Solution manufactured by Horizon Therapeutics.

Diclofenac sodium topical solution are indicated for the treatment of the pain of osteoarthritis of the knee(s).

Diclofenac sodium topical solution has an estimated market size of US $368 Million for the twelve months ending February 2023, as per IQVIA.